Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 2,038 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) VP Maria Dobek sold 2,038 shares of Janux Therapeutics stock in a transaction on Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the sale, the vice president owned 32,270 shares in the company, valued at $457,265.90. This represents a 5.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Janux Therapeutics Price Performance

JANX opened at $14.61 on Thursday. Janux Therapeutics, Inc. has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The firm’s fifty day moving average price is $14.41 and its two-hundred day moving average price is $17.11. The company has a market capitalization of $890.92 million, a P/E ratio of -7.94 and a beta of 2.58.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Analyst Ratings Changes

JANX has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. Wedbush dropped their target price on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. Guggenheim cut their price target on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a report on Friday, May 8th. Finally, Truist Financial upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.85.

Janux Therapeutics News Roundup

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush kept its Buy rating on Janux Therapeutics, reinforcing a constructive view on the stock. Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
• Positive Sentiment: HC Wainwright raised earnings estimates across multiple periods, including 2026, 2027, 2028, and 2029, suggesting improved expectations for the company’s future financial performance.
• Positive Sentiment: The firm’s Q2, Q3, and Q4 2026 EPS forecasts were all revised upward, which may be interpreted as a sign of improving operating trends.
• Neutral Sentiment: Janux Therapeutics’ vice president, Maria Dobek, sold 2,038 shares at an average price of $14.17, a transaction that slightly reduced insider ownership and may be viewed as a mild overhang. SEC Form 4 filing
• Neutral Sentiment: Despite the analyst optimism, Janux remains unprofitable, and the updated forecasts still point to losses in the coming years.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BML Capital Management LLC acquired a new position in Janux Therapeutics in the first quarter valued at about $2,154,000. Allspring Global Investments Holdings LLC acquired a new position in Janux Therapeutics during the 1st quarter worth about $2,452,000. Bleakley Financial Group LLC acquired a new position in Janux Therapeutics during the 1st quarter worth about $265,000. Hsbc Holdings PLC acquired a new position in Janux Therapeutics during the 1st quarter worth about $711,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Janux Therapeutics during the 1st quarter worth about $1,946,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.